NCT Number: NCT01845311
ReZolve2 Clinical Investigation
The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
St Vincent's Hospital, Sydney, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Primary Inclusion Criteria:
- Patient has evidence of myocardial ischemia or a positive functional study
- Patient has a normal CK-MB
- Target lesion has a visually estimated stenosis of ≥50% and <100%
- Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.75mm and ≤ 3.3mm
- Target lesion length must be ≤ 14mm
Primary Exclusion Criteria:
- Patient has experienced a myocardial infarction (CK-MB or Troponin > 5 X ULN) within 72 hours of the procedure
- Patient has a left ventricular ejection fraction < 30%
- Patient has unprotected lest main coronary disease with ≥50% stenosis
- The target vessel is totally occluded (TIMI Flow 0 or 1)
- Target lesion involves a bifurcation (a lesion with a side branch ≥ 2.0 mm in diameter containing a ≥ 50% stenosis).
- Target lesion is located within a bypass graft
- Target lesion has possible or definite thrombus
Treatment and study plan
Primary outcomes
-
Major Adverse Cardiac Events (MACE)
Time frame: 6 Months
-
Major Adverse Cardiac Events
Time frame: 12 Months
-
Late Lumen Loss
Time frame: 9 Months
Secondary outcomes
-
QCA derived parameters
Time frame: 9 Months
Late Loss, Restenosis Rate, % Diameter Stenosis & Minimum Lumen Diameter
-
Major Adverse Coronary Events
Time frame: 24, 36, 48 & 60 Months
Major Adverse Coronary Events - Combined events consisting of death, myocardial infarction and Target Lesion Revascularization
-
TLR
Time frame: 12,24,36,48 & 60 Months
Target Lesion Revascularization
-
TVR
Time frame: 12,24,36,48 & 60 Months
Target Vessel Revascularization
-
TVF
Time frame: 12, 24, 36, 48 & 60 Month
Target Vessel Failure
-
Acute Procedural Success
Time frame: Day 0
The percentage of patients meeting the Acute Technical Success criteria and the procedure results in a residual stenosis of <50 percent with no immediate (in-hospital) MACE.
-
Acute Technical Success
Time frame: Day 0
The percentage of patients with successful delivery and deployment of the scaffold in the intended lesion without device related complications.
-
Clinical Procedural Success
Time frame: 30 Days
The percentage of patients meeting the Acute Procedural Success criteria with no occurrence of a MACE event through 30 days.
Sponsors and collaborators
Lead sponsor
REVA Medical, Inc.
Industry
Registry information
Official study title
RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold
Acronym: RESTORE II
Important dates
- Study start
- 2013
- Primary completion
- 2014
- Study completion
- 2019
- First posted
- May 3, 2013
- Registry last updated
- Mar 29, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
NCT06281041
Arterial Occlusive Diseases, Arteriosclerosis
Gwangju, South Korea
View Trial DetailsRelation Between AI-QCA and Cardiac PET
NCT06397820
Arterial Occlusive Diseases, Arteriosclerosis
Gwangju, South Korea
View Trial DetailsRecoveryPlus Telerehab Platform Pilot Study
NCT05804500
Angina Pectoris, Angina, Stable
Washington D.C., District of Columbia, United States
View Trial DetailsXIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
NCT01106534
Arterial Occlusive Diseases, Arteriosclerosis
Birmingham, Alabama, United States
View Trial Details